Department of Radiology, Kyoto Prefectural University Graduate School of Medical Science, Kamigyo-ku, Kyoto, Japan.
Department of Dermatology, Kyoto Prefectural University Graduate School of Medical Science, Kamigyo-ku, Kyoto, Japan.
Medicine (Baltimore). 2021 Dec 10;100(49):e28210. doi: 10.1097/MD.0000000000028210.
Angiosarcoma of the scalp (ASS) is a rare solid tumor with a high risk of local recurrence. Effective treatment strategies are not currently available for angiosarcoma of the scalp (ASS). The aim of this study was to report the utility of high-dose-rate brachytherapy (HDRBT) as a boost treatment for ASS following total scalp irradiation using helical tomotherapy (HT). This is the first report of successful treatment of ASS using HT and HDRBT.
An 81-year-old woman presented with hemorrhagic nodular skin tumors of the scalp. The patient first noticed the scalp mass 3 months before consultation, which became significantly enlarged within a short period. The tumor was positioned mostly in the parietal area, although the skin color change was widely spread to the surrounding scalp.
The patient underwent biopsy of the skin lesion at the right parietal region, which revealed the presence of angiosarcoma on pathological examination. There was neither regional lymphadenopathy nor distant metastases on PET/CT.
Considering the patient's old age and poor performance status because of a history of cerebral infarction, we considered that she was eligible for definitive chemoradiotherapy of the scalp. We adopted an individual surface mold HDRBT boost of 18 Gy in three fractions following total scalp irradiation with 50 Gy in 25 fractions delivered using HT. Docetaxel (40 mg/m2) was administered every 4 weeks, concurrently with radiotherapy.
Treatment tolerance was good, and severe toxicity has not been observed to date. At 18 months after radiotherapy, the patient does not have any evidence of recurrence.
Customized surface mold HDRBT following total scalp irradiation using HT resulted in excellent disease control and minimal toxicity; thus, it may be a promising therapeutic option for ASS.
头皮血管肉瘤(ASS)是一种罕见的实体瘤,局部复发风险高。目前尚无有效的头皮血管肉瘤(ASS)治疗策略。本研究旨在报告螺旋断层放疗(HT)全头皮照射后,高剂量率近距离放疗(HDRBT)作为 ASS 辅助治疗的效果。这是首例成功使用 HT 和 HDRBT 治疗 ASS 的报道。
一位 81 岁女性因头皮出血性结节性肿瘤就诊。患者在就诊前 3 个月首次发现头皮肿块,短期内肿块显著增大。肿瘤主要位于顶区,但皮肤颜色改变广泛分布于周围头皮。
患者接受右顶区皮肤病变活检,病理检查显示存在血管肉瘤。18F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描(PET/CT)未见区域性淋巴结肿大或远处转移。
鉴于患者年龄较大,且因脑梗死病史导致一般状况较差,我们认为她适合接受头皮根治性放化疗。我们采用个体化表面模具 HDRBT 辅助治疗,在 HT 给予 50Gy/25f 全头皮照射后,分 3 次给予 18Gy 剂量。多西紫杉醇(40mg/m2)每 4 周给药 1 次,与放疗同步进行。
治疗耐受良好,目前尚未观察到严重毒性。放疗后 18 个月,患者无复发迹象。
HT 全头皮照射后使用个体化表面模具 HDRBT 治疗,可获得良好的疾病控制效果且毒性最小,因此可能是 ASS 的一种有前途的治疗选择。